Redx Pharma Plc
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.redxpharma.com
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Redx Pharma Plc
- Target Recruit Count
- 48
- Registration Number
- NCT05570058
- Locations
- 🇵🇱
Institute of Tuberculosis and Lung Diseases in Warsaw, Warsaw, Poland
🇨🇭University Hospital of Geneve, Geneva, Switzerland
🇮🇹Ospedale S. Giuseppe Milano, Milan, Italy
A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
- Conditions
- InflammationIdiopathic Pulmonary FibrosisLiver DiseasesKidney DiseasesNon-alcoholic SteatohepatitisFibrosis
- Interventions
- Drug: RXC007 Matching Placebo
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Redx Pharma Plc
- Target Recruit Count
- 90
- Registration Number
- NCT04931147
- Locations
- 🇬🇧
Simbec-Orion Clinical Pharmacology, Merthyr Tydfil, Mid Glamorgan, United Kingdom
A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)
- Conditions
- Advanced Solid Tumours
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Redx Pharma Ltd
- Target Recruit Count
- 45
- Registration Number
- NCT04907851
- Locations
- 🇦🇺
The Alfred Hospital - Alfred Health, Melbourne, Victoria, Australia
🇦🇺Wollongong Hospital, Wollongong, New South Wales, Australia
🇬🇧Barts Cancer Institute - Haemato-Oncology, London, United Kingdom
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Redx Pharma Ltd
- Target Recruit Count
- 25
- Registration Number
- NCT04907539
- Locations
- 🇺🇸
Providence Medical Foundation, Santa Rosa, California, United States
🇺🇸UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Community Health Network Cancer Center North - Community Hospital Network, Indianapolis, Indiana, United States
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Redx Pharma Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT03447470
- Locations
- 🇬🇧
Royal Marsden Hospital, Institute of Cancer Research, Sutton, Surrey, United Kingdom
🇬🇧Department of Oncology, Oxford, United Kingdom
🇬🇧Sir Bobby Robson Cancer Trials Research Centre, Newcastle, United Kingdom